BR0313522A - Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1 - Google Patents

Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1

Info

Publication number
BR0313522A
BR0313522A BR0313522-5A BR0313522A BR0313522A BR 0313522 A BR0313522 A BR 0313522A BR 0313522 A BR0313522 A BR 0313522A BR 0313522 A BR0313522 A BR 0313522A
Authority
BR
Brazil
Prior art keywords
expression
inhibit akt
antisense oligonucleotides
akt
inhibit
Prior art date
Application number
BR0313522-5A
Other languages
English (en)
Inventor
Heejeong Yoon
Lingjun Mao
Young Bok Lee
Chang Ho Ahn
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of BR0313522A publication Critical patent/BR0313522A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"USO DE OLIGONUCLEOTìDEOS ANTI-SENTIDO PARA INIBIR A EXPRESSãO DE AKT-1". Novos compostos oligonucleotídicos anti-sentido inibem a expressão de Akt-1 e também induzem citotoxicidade em várias linhagens de células cancerosas.
BR0313522-5A 2002-08-16 2003-08-13 Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1 BR0313522A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40401002P 2002-08-16 2002-08-16
PCT/US2003/025250 WO2004016215A2 (en) 2002-08-16 2003-08-13 Use of antisense oligonucleotides to inhibit the expression of akt-1

Publications (1)

Publication Number Publication Date
BR0313522A true BR0313522A (pt) 2005-06-28

Family

ID=31888309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313522-5A BR0313522A (pt) 2002-08-16 2003-08-13 Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1

Country Status (10)

Country Link
US (1) US7122527B2 (pt)
EP (1) EP1546180B1 (pt)
JP (1) JP4429906B2 (pt)
KR (1) KR101076146B1 (pt)
CN (1) CN100558740C (pt)
AU (1) AU2003258183B2 (pt)
BR (1) BR0313522A (pt)
CA (1) CA2495298C (pt)
ES (1) ES2423513T3 (pt)
WO (1) WO2004016215A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164271A1 (en) * 2004-01-20 2005-07-28 Sanjay Bhanot Modulation of glucocorticoid receptor expression
DE102005015660B4 (de) * 2005-04-06 2013-03-28 Forschungszentrum Jülich GmbH Niedertemperatur-Brennstoffzellenstapel sowie Verfahren zum Betreiben desselben
GB0516967D0 (en) * 2005-08-18 2005-09-28 Univ Southampton Inhibitors
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0520063D0 (en) * 2005-10-03 2005-11-09 Novartis Forschungsstiftung Methods for regulating metabolism and diagnosing disease
PT2563920T (pt) 2010-04-29 2017-05-26 Ionis Pharmaceuticals Inc Modulação da expressão de transtirretina
US9453017B2 (en) 2011-09-30 2016-09-27 Vanderbilt University Antiviral therapies with phospholipase D inhibitors
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
JP6228191B2 (ja) * 2012-05-23 2017-11-08 ジ・オハイオ・ステート・ユニバーシティ 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法
KR101461626B1 (ko) 2012-08-02 2014-11-28 서울대학교산학협력단 Ａｋｔ１ 억제제 및 소수성 항암제를 포함하는 항암용 약학적 조성물
AU2013359315B2 (en) * 2012-12-11 2016-12-08 Vanderbilt University Methods and compositions comprising Akt inhibitors and/or phospholipase D inhibitors
WO2020051243A1 (en) * 2018-09-04 2020-03-12 Ohio State Innovation Foundation Lipid nanoparticles and methods of using thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958733A (en) * 1997-04-18 1999-09-28 Smithkline Beecham Plc Threonyl tRNA synthetase polynucleotides
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US9534254B1 (en) * 1999-02-02 2017-01-03 Abbott Molecular Inc. Patient stratification for cancer therapy based on genomic DNA microarray analysis
WO2001092499A1 (en) * 2000-05-30 2001-12-06 Moelling Karin NUCLEIC ACID MOLECULES ENCODING A PROTEIN INTERACTING WITH Ser/Thr KINASE Akt

Also Published As

Publication number Publication date
JP4429906B2 (ja) 2010-03-10
AU2003258183A1 (en) 2004-03-03
CA2495298A1 (en) 2004-02-26
US20040265999A1 (en) 2004-12-30
KR20050088069A (ko) 2005-09-01
US7122527B2 (en) 2006-10-17
WO2004016215A2 (en) 2004-02-26
EP1546180B1 (en) 2013-07-03
KR101076146B1 (ko) 2011-10-21
CN1701077A (zh) 2005-11-23
EP1546180A2 (en) 2005-06-29
CN100558740C (zh) 2009-11-11
CA2495298C (en) 2010-10-19
ES2423513T3 (es) 2013-09-20
WO2004016215A3 (en) 2004-08-19
AU2003258183B2 (en) 2009-03-26
JP2006504410A (ja) 2006-02-09
EP1546180A4 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
BR0313522A (pt) Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
ZA200105821B (en) Novel cationic associative polyurethanes and their use as thickeners.
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
IL143379A0 (en) ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN AChE AND USES THEREOF
HUP0200308A2 (en) Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use
JP2003503309A5 (pt)
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
NZ591802A (en) Oral and personal care compositions and methods
GB0023056D0 (en) Use of algins in combating hard water,scale and the like
EP1102786A4 (en) AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS
AU2003255621A8 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
BRPI0407070A (pt) Oligonucleotìdeos antisentido que inibem a expressão de hif-1
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
ES2186596T1 (es) Uso de inhibidores de il-18.
TW200504210A (en) A nucleolin antisense inhibiting growth of cancer cell
WO2001066118A8 (en) 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
BR0009194A (pt) Composição do resorcinol
DK1137438T3 (da) Præparat med forbedret terapeutisk rækkevidde, indeholdende nukleotidsynteseinhibitorer
IL158600A0 (en) Ache antisense deoxyoligonucleotide as an anti-inflammatory agent
WO2005001030A3 (en) Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
EP1578711A4 (en) DITERPENOID COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTICANCER OR ANTIFUNGAL AGENTS
WO2004066949A8 (en) Antisense oligonucleotides that inhibit expression of hif-1
AU6143299A (en) Antisense oligonucleotide compositions targeted to beta1-adrenoceptor-specific mrna and methods of use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]